A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection
Status:
Completed
Trial end date:
2022-03-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, multiple-ascending dose
phase Ib study of HH-003 injection, which is a monoclonal antibody targeting Hepatitis B
virus. This study aims to evaluate the safety, tolerability and pharmacokinetics of HH-003
injection in treatment-naive participants chronically infected with hepatitis B virus.